Dmard

An automated best practice advisory within the electronic health record can improve infectious disease screening in patients with autoimmune and rheumatic conditions, according to data published in Arthritis Care & Research.

PHILADELPHIA — Patients with psoriatic arthritis who achieved clinical disease control demonstrated clinically meaningful improvements across a broad range of patient-reported outcomes, including pain, fatigue, physical function and work productivity.

PHILADELPHIA — The initiation of disease-modifying antirheumatic drugs among U.S. veterans with active rheumatoid arthritis requires improvement, regardless of rural or urban setting, according to a presentation at ACR Convergence 2022.

PHILADELPHIA — Prescribing patterns of fellows seeing patients with rheumatoid arthritis in an urban, academic hospital system aligned with the teaching practices of faculty, according to findings presented at ACR Convergence 2022.

PHILADELPHIA — Patients with rheumatoid arthritis frequently switched between JAK inhibitors in Australia, according to a presentation at ACR Convergence 2022.

What does the PAPA spectrum disorder teach us about SAPHO? Is SAPHO an autoinflammatory condition or part of the SpA spectrum? Why have antibiotics been used to treat this condition? Find out in this episode!

Although data supporting cannabis use in patients with rheumatic diseases “continue to grow,” most of the recent literature have been reviews rather than primary research, according to a review published in Current Rheumatology Reports.

Molecular signature response classifier-assisted rheumatoid arthritis treatment selection may improve real-world results in patients with rheumatoid arthritis, according to data published in Expert Opinion on Biological Therapy.

Despite guidelines recommending early and aggressive therapy in rheumatoid arthritis, disease-modifying antirheumatic drug adoption for older patients remains low, according to data published in ACR Open Rheumatology.

Nurse-led education for patients with rheumatoid arthritis or spondyloarthritis, who are beginning biologic disease-modifying antirheumatic drugs, is effective at changing behaviors to prevent adverse events, according to data.